Glenmark gains as its arm successfully completes preclinical evaluation phase of ‘GBR1302’

16 Sep 2015 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 1021.50, up by 5.20 points or 0.51% from its previous closing of Rs. 1016.30 on the BSE.

The scrip opened at Rs. 1029.00 and has touched a high and low of Rs. 1030.00 and Rs. 1016.10 respectively. So far 20,366 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 677.85 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 1041.00 and Rs. 976.80 respectively. The current market cap of the company is Rs. 28,822.00 crore.

The promoters holding in the company stood at 46.44% while Institutions and Non-Institutions held 42.70% and 10.86% respectively.

Glenmark Pharmaceuticals’ subsidiary Glenmark Pharmaceuticals S.A. (GPSA) has completed the Phase 1 supporting studies and the submission of a clinical trial application to the Paul-Ehrlich Institute in Germany with a novel clinical development candidate, GBR 1302. GBR 1302 is a HER2xCD3 bi-specific antibody based on the company’s proprietary BEATTM platform. GBR 1302 is the first clinical development candidate based on the BEATTM technology. The company expects to obtain approval for the initiation of clinical studies with GBR1302 during this financial year.

GBR 1302 material for Phase 1 clinical trials was manufactured in the company’s GMP production unit in Switzerland. HER2, also known as HER2/neu, or receptor tyrosine-protein kinase erbB-2, is the target of the multibillion dollar antibody cancer drugs trastuzumab, pertuzumab and trastuzumab emtansine and is implicated in breast cancer, ovarian, gastric, and certain uterine cancers.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues.


Glenmark Pharma Share Price

2036.00 6.40 (0.32%)
31-Dec-2025 15:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1272.00
Cipla 1507.30
Zydus Lifesciences 912.75
Lupin 2104.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×